JUBILANT DRAXIMAGE is a pharmaceutical company focused on Oncology, Neurology. Key products include TECHNETIUM TC 99M MERTIATIDE KIT.
JUBILANT DRAXIMAGE's Key Drugs
JUBILANT DRAXIMAGE's core commercial portfolio centers on TECHNETIUM TC 99M MERTIATIDE KIT, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.
JUBILANT DRAXIMAGE's Recent FDA Approvals
New NDA/BLA approvals for JUBILANT DRAXIMAGE over the last two years — novel drugs only, excluding generics and label supplements.
JUBILANT DRAXIMAGE's Therapeutic Areas
JUBILANT DRAXIMAGE's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 1 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
JUBILANT DRAXIMAGE's Top Competitors
JUBILANT DRAXIMAGE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
JUBILANT DRAXIMAGE Pipeline Snapshot
Active clinical trials for JUBILANT DRAXIMAGE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TECHNETIUM TC 99M MERTIATIDE KIT leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1976-11-16
- Latest
- 2023-01-30
- Applications
- 7